117 results
8-K
EX-99.1
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
, industry or political conditions in the United States or internationally. There can be no assurance that Syros will be able to complete the offering
424B5
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Prospectus supplement for primary offering
4:53pm
prospectus we may authorize to be delivered or made available to you. We and the underwriters take no responsibility for, and can provide no assurance … could alter the tax consequences to non-U.S. holders described in this prospectus supplement. In addition, there can be no assurance that the Internal
424B5
9rqa9n
1 May 23
Prospectus supplement for primary offering
4:06pm